Immunai

??This week, we’re kicking off “Inside Immunai,” a monthly series highlighting the unique expertise of our team! We start by shining the spotlight on Shikha Nayar, our Systems Immunology Team Lead in our External Collaborations group. Shikha’s role involves extracting meaningful data from patient and preclinical studies and tackling challenging questions like why patients aren’t responding to certain drugs in clinical trials. Shikha empowers her team to find creative ways to answer tough questions and distill insights that are biologically meaningful and differentiated. One of the most exciting projects Shikha has worked on involves identifying novel targets in the IBD space. Having completed her Ph.D. in this field, she has seen the landscape evolve over the past decade and is excited to see how we can work with collaborators to move the needle forward. Outside of work, Shikha has a hidden talent—she's a passionate singer and has been performing with the Young New Yorkers Chorus for the last 10 years. Come watch a performance of hers this winter! ?? Shikha's enthusiasm for Immunai’s mission is palpable. Thank you for being an integral part of our team. You can explore opportunities with Immunai here: https://lnkd.in/dri8bPpS #Biotech #MachineLearning #Immunology #Innovation #Healthcare

I had the pleasure of hosting?Ruth Reader?of?POLITICO?at?Immunai’s New York office earlier this week. We chatted about the impact of #AI on drug development and how it can map the immune system to help drugmakers better understand their therapies. Our discussion made its way into?POLITICO's Future Pulse newsletter, which covers the ideas and innovators that are shaping health care. At Immunai, we view drug effects on our immune system like a complex domino network effect—each domino action leads to another, eventually leading to the clinical outcome, and with our immune mapping we are generating data that can explain why certain drugs work for some patients and not for others. With the FDA increasingly requesting granular data to support drug approvals, this data is becoming more critical, especially for cancer treatments, where drugs have to be better than standard of care therapies. Thank you for the discussion, Ruth! You can read more about Immunai’s work in today’s newsletter:

Once in a while I am asked how I feel about one company or another in our competitive space having signed a nice collaboration or secured a financing round. Assuming the company is doing something "real" (there are many companies not generating anything real or exciting just PR and marketing of AI), I’m happy for the company. Why am I happy to hear such news? 1. This is not a zero sum-game. The success of one company does not imply bad things for other companies in the space. In fact, the real concern about #AI in biotech is the opposite, namely, that platform companies leveraging AI for drug development would fail to get FDA clearance in the years to come and that we will all fail. In this sense, we are all playing for the same team: demonstrating that AI-based platforms can bring a real tangible value in #Tx discovery and development is crucial, and the more successes our companies would bring, the clearer this narrative will become.? 2. Before being a CEO, I am a scientist, and before that I am a human being- seeing biotechnology companies advancing their capabilities for the better of patient outcomes excites me as a scientist and as a person and I will continue to cheer for companies doing great science and engineering, even if they compete with me. 3. I truly believe in competition. I think that the only way to become great is by competing with greatness. This is true in sports, true in science, and true in business. Don’t aim to win by running away from competition, aim to win by beating the competition, and Immunai aims for the gold. 4. Immunai's UVP (unique value proposition) is truly unique: we are unlocking immune system intelligence with our AI model of the immune system on the largest clinical database of the immune system. Put more simply: we are the #ChatGPT for drug development, where we are able to interrogate the immune system to answer the drug development questions. That’s something others are not doing, and something that is incredibly difficult to build. Good luck to all our fellow companies developing AI-based platforms in the biotech space, we should all work even harder to bring better patient outcomes! See you at the podium ;) #AIinBiotech #Competition #Patientoutcomes

Join Us for the Chomsky Annual Single Cell Seminar! July 3, 9:00 AM EDT / 4:00 PM IDT (registration required). We are honored to invite you to the?Chomsky Annual Single Cell Seminar, an annual tribute to the life and scientific legacy of Elad Chomsky,?an early Immunai employee, exceptional scientist, and dear friend whom we lost to pancreatic cancer. In this year’s seminar we are privileged to host two prominent researchers in the single cell community, Dr. Leeat Keren?and Dr. Mor Nitzan?as well as our very own Dr. Florian Uhlitz. In a manner true to Elad, we are sure this will be a thought provoking and inspiring seminar and invite you to join us! Event Details:? Date: July 3, 2024? Time:?4:00 PM IDT / 9:00 AM EDT Location:?online. Register now?to secure your spot: https://lnkd.in/dqJDBxeh #SingleCellSeminar #ChomskyAnnual #SingleCellResearch #SpatialTranscriptomics #ComputationalBiology #SystemsBiology #ScientificResearch